Bionomics Ltd - ESG Rating & Company Profile powered by AI
This analysis of Bionomics Ltd incorporates intelligence from across the internet and also from public filings by Bionomics Ltd. The report of Bionomics Ltd was prepared by All Street Sevva using cutting edge NLP. Scroll down to the end of the page for potential risks for Bionomics Ltd based on industry, location and size.
Bionomics Ltd in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 2.6; made up of an environmental score of 2.7, social score of 3.2 and governance score of 2.0.
2.6
Low ImpactEnvironmental
Social
Governance
Peer Group Comparison
| Rank | Company | SDG Transparency Score ⓘ | Performance |
|---|---|---|---|
| 1 | Caladrius Biosciences Inc | 8.0 | High |
| 1 | Can Fite Biopharma Ltd | 8.0 | High |
| ... | ... | ... | |
| 1437 | Valenta Farmatsevtika AO | 2.7 | Medium |
| 1437 | Wockhardt Bio AG | 2.7 | Medium |
| 1481 | Bionomics Ltd | 2.6 | Medium |
| 1481 | CTI Biopharma Corp | 2.6 | Medium |
| 1481 | Cannara Biotech Inc | 2.6 | Medium |
| ... | ... | ... | |
| 1970 | Zyden Gentec Ltd | 0.0 | Low |
| 1970 | iNtRON Biotechnology Inc | 0.0 | Low |
| ... | ... | ... |
Frequently Asked Questions
Does Bionomics Ltd have an accelerator or VC vehicle to help deliver innovation?
Sign up for free to unlockDoes Bionomics Ltd disclose current and historical energy intensity?
Sign up for free to unlockDoes Bionomics Ltd report the average age of the workforce?
Sign up for free to unlockDoes Bionomics Ltd reference operational or capital allocation in relation to climate change?
Sign up for free to unlockDoes Bionomics Ltd disclose its ethnicity pay gap?
Sign up for free to unlockDoes Bionomics Ltd disclose cybersecurity risks?
Sign up for free to unlockDoes Bionomics Ltd offer flexible work?
Sign up for free to unlockDoes Bionomics Ltd have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Sign up for free to unlockDoes Bionomics Ltd disclose the number of employees in R&D functions?
Sign up for free to unlockDoes Bionomics Ltd conduct supply chain audits?
Sign up for free to unlockDoes Bionomics Ltd disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Sign up for free to unlockIs there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Sign up for free to unlockDoes Bionomics Ltd conduct 360 degree staff reviews?
Sign up for free to unlockDoes Bionomics Ltd disclose the individual responsible for D&I?
Sign up for free to unlockDoes Bionomics Ltd disclose current and historical air emissions?
Sign up for free to unlockIs there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Sign up for free to unlockIs executive remuneration linked to climate performance?
Sign up for free to unlockDoes the Board describe its role in the oversight of climate-related risks and opportunities?
Sign up for free to unlockDoes Bionomics Ltd disclose current and / or historical scope 2 emissions?
Sign up for free to unlockDoes Bionomics Ltd disclose water use targets?
Sign up for free to unlockDoes Bionomics Ltd have careers partnerships with academic institutions?
Sign up for free to unlockDid Bionomics Ltd have a product recall in the last two years?
Sign up for free to unlockDoes Bionomics Ltd disclose incidents of discrimination?
Sign up for free to unlockDoes Bionomics Ltd allow for Work Councils/Collective Agreements to be formed?
Sign up for free to unlockHas Bionomics Ltd issued a profit warning in the past 24 months?
Sign up for free to unlockDoes Bionomics Ltd disclose parental leave metrics?
Sign up for free to unlockDoes Bionomics Ltd disclose climate scenario or pathway analysis?
Sign up for free to unlockDoes Bionomics Ltd disclose current and / or historical scope 1 emissions?
Sign up for free to unlockAre Operating Expesnses linked to emissions reduction?
Sign up for free to unlockDoes Bionomics Ltd disclose the pay ratio of women to men?
Sign up for free to unlockDoes Bionomics Ltd support suppliers with sustainability related research and development?
Sign up for free to unlockDoes Bionomics Ltd disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Sign up for free to unlockDoes Bionomics Ltd reflect climate-related risks in its financial statements?
Sign up for free to unlockIs there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Sign up for free to unlockIs Bionomics Ltd involved in embryonic stem cell research?
Sign up for free to unlockDoes Bionomics Ltd disclose GHG and Air Emissions intensity?
Sign up for free to unlockDoes Bionomics Ltd disclose its waste policy?
Sign up for free to unlockDoes Bionomics Ltd report according to TCFD requirements?
Sign up for free to unlockDoes Bionomics Ltd disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Sign up for free to unlockDoes Bionomics Ltd disclose energy use targets?
Sign up for free to unlockDoes Bionomics Ltd disclose its Renewable Energy targets?
Subscription requiredAre emissions metrics verified by STBi?
Subscription requiredDoes Bionomics Ltd have a policy relating to cyber security?
Sign up for free to unlockHave a different question?
Potential Risks for Bionomics Ltd
These potential risks are based on the size, segment and geographies of the company.
Bionomics Limited, a clinical stage biopharmaceutical company, discovers and develops novel drug candidates for the treatment of central nervous system disorders and cancers. The company's lead drug candidate includes BNC210, a negative allosteric modulator of the a7 nicotinic acetylcholine receptor, which is in phase 2 clinical trial for the treatment of social anxiety disorder and phase 2b to treat post-traumatic stress disorder. It also develops BNC101, a monoclonal antibody that has completed phase 1 clinical trial that targets cancer stem cells; and BNC105, which is in phase 2 clinical trial for the treatment of refractory colorectal cancer and phase 1 clinical trial for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia. Bionomics Limited was incorporated in 1996 and is based in Eastwood, Australia.